Welcome to our dedicated page for 4D Molecular Therapeutics news (Ticker: FDMT), a resource for investors and traders seeking the latest updates and insights on 4D Molecular Therapeutics stock.
4D Molecular Therapeutics, Inc. (Nasdaq: FDMT) is a late-stage biotechnology company developing durable, disease-targeted genetic medicines. News about 4D Molecular Therapeutics often focuses on progress in its lead programs, 4D-150 for retinal vascular diseases and 4D-710 for cystic fibrosis lung disease, as well as corporate, financial and partnership developments.
For ophthalmology, company updates highlight clinical data and milestones for 4D-150 in wet age-related macular degeneration and diabetic macular edema. These include interim results from the PRISM Phase 1/2 trial, enrollment and design details for the 4FRONT Phase 3 program, and plans for global Phase 3 trials in DME. News items also cover collaborations, such as the license and development agreement with Otsuka Pharmaceutical for 4D-150 in Asia-Pacific markets.
In pulmonology, 4DMT news includes interim clinical data from the AEROW Phase 1/2 trial of 4D-710 in cystic fibrosis lung disease, describing CFTR transgene expression, lung function measures and dose selection for Phase 2. Additional coverage addresses external support, including an equity investment from the Cystic Fibrosis Foundation to help advance 4D-710.
Investors can also find announcements on equity offerings, cash runway guidance, leadership changes, board appointments, employment inducement grants and participation in healthcare and investor conferences. This news page aggregates these updates so readers can follow clinical progress, strategic partnerships, capital markets activity and governance developments related to FDMT over time.
4D Molecular Therapeutics (Nasdaq: FDMT) reported Q1 2026 results and operational updates on May 7, 2026. Key clinical milestones: 4FRONT-1 randomization complete (N=523); 4FRONT-1 topline data expected H1 2027; 4FRONT-2 enrollment expected complete H2 2026 with topline H2 2027. PRISM 2-year data due Q3 2026; SPECTRA 2-year data due H2 2026. Cash, cash equivalents and marketable securities: $458 million as of March 31, 2026, expected to fund operations into H2 2028. Q1 2026 R&D expense: $65.0 million; net loss: $68.8 million.
4D Molecular Therapeutics (Nasdaq: FDMT) announced management will present and hold one-on-one investor meetings at two May 2026 healthcare conferences: BofA Securities 2026 Healthcare Conference on May 13, 2026 at 1:40 p.m. PT, and RBC 2026 Global Healthcare Conference on May 19, 2026 at 2:35 p.m. ET. Archived webcasts will be available for up to one year on the company’s Investors website.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on April 14, 2026 its compensation committee granted a total of 67,600 Restricted Stock Units (RSUs) to five new non-executive employees under the company’s 2025 Employment Inducement Award Plan pursuant to Nasdaq Rule 5635(c)(4).
The grants were made to induce new employees to join the company and were issued under the amended inducement plan.
4D Molecular Therapeutics (Nasdaq: FDMT) reported full‑year 2025 results and operational milestones, highlighting rapid Phase 3 enrollment for 4D‑150, strategic partnership with Otsuka, and a strengthened balance sheet. Key figures: $514 million cash and marketable securities and an $85 million upfront collaboration payment.
Trials: 4FRONT‑1 enrollment completed early with topline wet AMD data expected H1 2027; PRISM and SPECTRA 2‑year readouts expected mid‑2026 and H2 2026; 4D‑150 DME Phase 3 to start Q3 2026.
4D Molecular Therapeutics (Nasdaq: FDMT) said management will present and hold one-on-one investor meetings at upcoming conferences in March 2026.
Scheduled events include the Leerink Partners Mountain Meeting (March 22–25, 2026) and a presentation at the RBC Capital Markets Global Ophthalmology Conference on March 24, 2026 at 3:45 p.m. GMT. An archived webcast will be available for up to one year on the company Investors site.
4D Molecular Therapeutics (Nasdaq: FDMT) said management will present and hold one-on-one investor meetings at three healthcare conferences in March 2026.
Presentations are scheduled at TD Cowen on March 3, 2026 at 10:30 a.m. ET, Leerink on March 10, 2026 at 4:20 p.m. ET, and Barclays on March 12, 2026 at 9:00 a.m. ET. Webcasts will be archived for up to one year on the company Investors site.
4D Molecular Therapeutics (Nasdaq: FDMT) announced that on February 10, 2026 its compensation committee granted 124,200 Restricted Stock Units (RSUs) to nine new non-executive employees under the Company’s 2025 Employment Inducement Award Plan.
The awards were made pursuant to Rule 5635(c)(4) of The Nasdaq Global Market to induce new employees to join the company.
4D Molecular Therapeutics (Nasdaq: FDMT) announced completion of enrollment for 4FRONT-1, the first Phase 3 registrational trial of 4D-150 in wet age-related macular degeneration (wet AMD), achieved in approximately 11 months and with over-enrollment expected to exceed 500 randomized patients.
Topline primary endpoint data for 4FRONT-1 is expected in H1 2027; global activation for 4FRONT-2 continues with enrollment on track for completion in H2 2026 and topline data expected in H2 2027.
4D Molecular Therapeutics (Nasdaq: FDMT) announced on January 17, 2026 that its compensation committee granted 23,600 Restricted Stock Units (RSUs) on January 13, 2026 to four new non-executive employees.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan, which the board approved in February 2025 under Nasdaq Rule 5635(c)(4) to permit equity grants that induce new hires to join the company.
4D Molecular Therapeutics (Nasdaq: FDMT) provided a 2026 corporate update highlighting accelerated late-stage retinal programs, leadership changes and financial runway. Key clinical milestones include an increased 4FRONT Phase 3 target enrollment to 480 patients per trial (≈90% power), 381 patients randomized or approved to randomize in 4FRONT-1 as of Jan 6, 2026, with North America enrollment on track to complete in Q1 2026 and topline data expected in H1 2027. Ex-U.S. enrollment for 4FRONT-2 aims to finish in H2 2026 with topline in H2 2027. PRISM 2-year Phase 2b data expected mid-2026; SPECTRA 2-year data and DME Phase 3 plans expected in H2 2026. Leadership updates include board addition Glenn Sblendorio and executive promotions, and cash of $514 million is expected to fund operations into H2 2028.